dsm-firmenich announces partnership with Zerion for CBD innovation
The company says patients currently have to self-administer large volumes of cannabidiol (CBD) to achieve a helpful therapeutic outcome. The partnership grants dsm-firmenich global access to ZERION AS’s Dispersome technology, developed to significantly increase the bioavailability of oral CBD compared to commercially available CBD oils. The companies say that not ... Read More